- Laurus conceded the patent’s validity and that its copycat would infringe, and Laurus agreed to be blocked from making copies until the patent has expired “unless otherwise specifically authorized” by Actelion, according to
consent judgmentapproved Friday in federal court in Wilmington, Delaware
- Judgment mentions license agreement but provides no further details
- Opsumit had U.S. sales of $729 million during the first nine months of 2020, up from $581 million during the same period ...
Jan. 25, 2021, 3:34 PM